MedTrace Logo

The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment

NCT05486468 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-08-11

No results posted yet for this study

Summary

The Use of Two YUTIQ versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial)

Conditions

  • Uveitis
  • Uveitis, Posterior
  • Uveitis, Anterior
  • Uveitis, Intermediate

Interventions

DRUG

Yutiq 0.18 MG Drug Implant

YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for intravitreal injection

OTHER

Sham Injection

Sham injection

Sponsors & Collaborators

  • Eye Point Pharmaceuticals

    collaborator UNKNOWN

  • ANI Pharmaceuticals

    collaborator INDUSTRY

  • Texas Retina Associates

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-05
Primary Completion
2026-07-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05486468 on ClinicalTrials.gov